ID: ALA2425066

Max Phase: Preclinical

Molecular Formula: C19H18F2N2O2

Molecular Weight: 344.36

Molecule Type: Small molecule

Representations

Canonical SMILES:  N[C@H]1C[C@@H](N2Cc3ccccc3C2=O)CO[C@@H]1c1cc(F)ccc1F

Standard InChI:  InChI=1S/C19H18F2N2O2/c20-12-5-6-16(21)15(7-12)18-17(22)8-13(10-25-18)23-9-11-3-1-2-4-14(11)19(23)24/h1-7,13,17-18H,8-10,22H2/t13-,17+,18-/m1/s1

Standard InChI Key:  KWHHFCJEDQHJMW-JEBQAFNWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 344.36

Molecular Weight (Monoisotopic): 344.1336

AlogP: 2.78

#Rotatable Bonds: 2

Polar Surface Area: 55.56

Molecular Species: BASE

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.71

CX LogP: 2.26

CX LogD: 0.93

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.91

Np Likeness Score: -0.41

References

1. Biftu T, Qian X, Chen P, Feng D, Scapin G, Gao YD, Cox J, Roy RS, Eiermann G, He H, Lyons K, Salituro G, Patel S, Petrov A, Xu F, Xu SS, Zhang B, Caldwell C, Wu JK, Lyons K, Weber AE..  (2013)  Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].,  23  (19): [PMID:23972441] [10.1016/j.bmcl.2013.07.061]

Source

Source(1):

• Scientific Literature